



Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive

#02-01 Amnios

Singapore 138622

**For Immediate Release**

## **Singapore Institute of Advanced Medicine Holdings looks to drive proton therapy patient flow as it enters into a medical services agreement with Icon Singapore, enhancing treatment options and access for cancer patients**

- **Incremental Business:** Provision of proton therapy treatment to Icon’s patients may increase patient flow and revenue for PTPL. This collaboration will increase treatment options and enhance access for Icon’s cancer patients.
- **Long-Term Agreement:** The agreement will be valid for an initial term of 3 years commencing from 1 July 2024, thereby ensuring a steady flow of patients in the long run.

**Singapore, 26 June 2024** – Singapore Institute of Advanced Medicine Holdings Ltd. (“**SAM Holdings**” or the “**Company**”, and together with its subsidiaries, the “**Group**”), has on 26 June 2024 entered into a medical services agreement with Icon SOC Pte. Ltd. (“**Icon**”) through its wholly-owned subsidiary Proton Therapy Pte. Ltd. (“**PTPL**”) for the provision of proton therapy treatment medical services to Icon’s patients.

This collaboration amalgamates PTPL’s know-how and core capabilities in proton therapy with Icon’s deep expertise and network in oncology. It enables PTPL access to Icon’s wider patient network while enhancing the provision of comprehensive cancer care at Icon through the addition of PTPL’s proton therapy capabilities. The term of the agreement will commence from 1 July 2024 for an initial term of 3 years.

Icon is primarily engaged in the business of provision of medical and radiation oncology services. It is a part of the Icon Group – Australia’s largest dedicated provider of cancer care. Today, Icon Group delivers over 3.5 million patient interactions across more than 50 cancer centres, five compounding facilities and the management of 70 plus pharmacies.

Commenting on the medical services agreement, Dr Djeng Shih Kien, Executive Director and CEO, and founder, of SAM Holdings, said, “The partnership underlines what we had envisioned when we set out on this journey to improve the quality of life of cancer patients. We are excited to partner with Icon Singapore as it allows us to enhance our reach and impact the life of many more cancer patients throughout the region.”



Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive  
#02-01 Amnios  
Singapore 138622

“At Icon, the patient is at the heart of everything we do. This collaboration marks our commitment to provide new and novel treatment options for our patients, enhancing our current suite of best-in-class cancer treatments and technologies.” said Serena Wee, Chief Executive Officer of Icon ASEAN and Hong Kong.

- - End - -

*Singapore Institute of Advanced Medicine Holdings Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("SGX-ST") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").*

*This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg).*

### **About Singapore Institute of Advanced Medicine Holdings Ltd. ("SAM Holdings")**

Incorporated in 2011, SAM Holdings is a healthcare service provider using advanced technology for early and accurate diagnosis and offering appropriate treatments to achieve better outcomes and quality of life for our patients. The Group's services cater to a wide spectrum of diseases and health conditions including, but not limited to, cancer, neurodegenerative and cardiovascular disease detection, and treatment. The Group is primarily engaged in two key business segments: (i) Medical Diagnostics and Treatments; and (ii) Radiation Therapy and Medical Oncology Services.

The goal is to create a comprehensive one-stop ambulatory cancer centre to undertake the challenges to fight cancer. The Group aims to do this by bringing together a dedicated team of professionals and experts from the industry who will empower them to take away the fear of cancer by finding the answers and solutions for the diagnosis, treatment, and ongoing quality of life improvements for cancer patients. For more information, please visit SAM Holdings' website at [www.advancedmedicine.sg](http://www.advancedmedicine.sg).

### **About Icon ASEAN**

Icon Cancer Centre – Singapore



**Singapore Institute of Advanced Medicine Holdings Ltd.**

1 Biopolis Drive  
#02-01 Amnios  
Singapore 138622

Icon Cancer Centre in Singapore was established in 2016 with the acquisition of Singapore Oncology Consultants (SOC) - the first private oncology group in Singapore founded by an experienced cohort of clinicians. Currently, there are six cancer centres in Singapore offering a mix of medical oncology, haematology, radiation oncology, paediatric oncology and research ensuring a comprehensive approach to cancer care.

For more information visit [iconcancercentre.sg](http://iconcancercentre.sg)

#### Icon Oncology – Malaysia

With a shared mission to enhance cancer care in Malaysia, Icon Group, Australia's largest dedicated provider of cancer care, and Sunsuria Healthcare, a subsidiary of Sunsuria Berhad, entered into a joint venture agreement to set up Icon Sunsuria Sdn Bhd. In January 2024, we opened our first centre in Island Hospital to provide comprehensive cancer care to the people of Malaysia. For more information visit [icononcology.com.my](http://icononcology.com.my)

**Issued for and on behalf of Singapore Institute of Advanced Medicine Holdings Ltd.  
By Financial PR Pte Ltd**

For more information please contact:

Shivam SARAF / Kamal SAMUEL

Financial PR Pte Ltd

Tel: 6438 2990 / Fax: 6438 0064

E-mail: [shivam@financialpr.com.sg](mailto:shivam@financialpr.com.sg) / [kamal@financialpr.com.sg](mailto:kamal@financialpr.com.sg)